Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • September 2021 •
  • 143 pages •
  • Report ID: 6154344 •
  • Format: PDF
The global non-melanoma skin cancer treatment market grew at a CAGR of around 5% during 2015-2020.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient’s body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further. Looking forward, the analyst expects the global non-melanoma skin cancer treatment market to continue its moderate growth during the next five years.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global non-melanoma skin cancer treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, indication and end use.

Breakup by Treatment Type:
Chemotherapy
Radiation Therapy
Photodynamic Therapy
Others

Breakup by Indication:
Basal Cell Carcinoma
T-Cell Lymphoma
Squamous Cell Carcinoma
Others

Breakup by End Use:
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Others

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG and Sun Pharmaceutical Industries Limited.

Key Questions Answered in This Report:
How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
What is the degree of competition in the industry?